Skip to main content
Clinical Trials/EUCTR2010-021526-36-DE
EUCTR2010-021526-36-DE
Active, not recruiting
Phase 1

Dynamic and high-resolution MR angiography of the supraaortic vessels at 3 Tesla: Performance of Gadobutrol (Gadovist) in comparison to Gedobenate Dimeglumine (Multihance) and Gadoterate Meglumine (Dotarem) at equimolar dose (0.1 mmol/kg BW) in volunteers and patients with carotid artery stenosis - Gadovist in MR angiography

Klinikum der Universität München0 sites20 target enrollmentDecember 3, 2010

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Supraaortic vessel disease
Sponsor
Klinikum der Universität München
Enrollment
20
Status
Active, not recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 3, 2010
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Volunteer part:
  • 1\.age: at least 18 years
  • 2\.no history of cardiovascular disease
  • 3\.willing to undergo all study procedures
  • 4\.has voluntarily signed and dated the informed consent form
  • Women of childbearing potential:
  • 5\.a negative pregnancy test (urine test) on the day of contrast agent administration
  • 6\.use of a highly effective method of birth control during the duration of the study (e.g. implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence or vasectomised partner)
  • Patient part:
  • 1\.age: at least 18 years

Exclusion Criteria

  • Volunteer part:
  • 1\.if female:, pregnant or nursing
  • 2\.history of renal disease, subjects in the perioperative liver transplantation period and / or with acute or chronic severe renal impairment
  • 3\.GFR \<60ml/m²/1\.73m² (MDRD) as determined from a serum creatinine value not older than 4 weeks before MR contrast agent injection
  • 4\.contraindications against MR imaging (e.g. subjects with implanted ferromagnetic objects (pacemaker, vascular clip))
  • 5\.contraindications against any of the three MR contrast agents (e.g. aggravation of anaphylactic\-like reactions in patients on beta\-blockers, and particularly in the presence of bronchial asthma, low seizure threshold in patients with CNS disorders, patients with uncorrected hypokalemia, severe cardiovascular disease)
  • 6\.severe claustrophobia
  • 7\.history of anaphylactoid or anaphylactic reaction to any allergen (e.g. hay fever, urticaria, asthma, history of sensitivity to benzyl alcohol, etc.) including drugs and contrast agents
  • 8\.having received any investigational drug within 7 days prior to entering this study
  • 9\.planned to receive any investigational drug during the study period

Outcomes

Primary Outcomes

Not specified

Similar Trials